Objective: This study aimed to evaluate the cost-utility of the homebased care policy versus the no home-based care policy of factor VIII and factor IX concentrate in Thai patients with hemophilia A and B who had no inhibitor or less than 5 Bethesda units. Methods: A Markov model was used to evaluate the cost utility of the two policies. The first policy was "no home-based care" in which patients were treated with blood components only when admitted at the hospital but without home treatment. The second policy was "home-based care" in which factors were prescribed and infused for treatment of early bleeding episodes at home. Input parameters related to clinical and cost were obtained from primary data collection at the National Health Security Office, while patients' quality of life was surveyed from mailed questionnaires. Both costs and health outcomes were discounted at 3%. One-way analysis and probabilistic sensitivity analysis were performed to assess uncertainty surrounding model parameters. Results: Based on governmental perspective, the "home-based care" policy had cost saving in patients with moderate and severe hemophilia when compared with the "no home-based care" policy; in patients with mild hemophilia, the incremental cost-effectiveness ratio was 80,542 Thailand baht (THB) or US $2,684.73 (US $1 ¼ 30 THB). Conclusions: At the ceiling threshold of one time of gross domestic product per capita (120,000 THB per quality-adjusted life-year gained), the "home-based care" policy was cost-effective when compared with the "no homebased care" policy.
Introduction
Hemophilia A and B are hereditary X-linked disorders caused by a deficiency of clotting factor VIII and IX in the blood [1, 2] . The disease can be defined as mild, moderate, or severe depending on the degree of deficiency of the factor. Patients with hemophilia require lifelong replacement therapy to control bleeding episodes, with impact on their quality of life. Hemophilia, however, is not given the priority it deserves in economically less-developed countries because there is a high number of other serious health problems. The replacement therapy is mainly limited to locally prepared fresh frozen plasma, cryoprecipitate, and cryo-removed plasma, which are not virus-inactivated products. Patients risk contracting transfusion-transmitted diseases. The virus-inactivated factor concentrate is seldom used because of the high price. Impressively, the established home-based care for 85 patients with hemophilia at the International Hemophilia Training Center-Bangkok, with limited resources, has significantly decreased the risk of death and increased the survival time [3] . Home care treatment can be adopted even by parents with low literacy.
Factor VIII and factor IX concentrate have been listed in the National Drug List, an essential drug, since 2008 to support patients on home treatment under the Universal Coverage Scheme [4] . The mean per capita factor VIII use in Thailand in 2010, however, was 0.077 IU per year, compared with the global use at 1.433 IU per year [5] . In 2012, only 1171 or one fourth of estimated patients with hemophilia in Thailand were registered and able to access the medicines. No study, however, has been conducted in Thailand considering cost utility of home-based care treatment. This study was conducted to evaluate the cost utility of the home-based care policy versus the no home-based care policy of factor VIII and factor IX concentrate in Thai patients with hemophilia A and B who had no inhibitor or less than 5 Bethesda units (BU).
Methods
Our study conducted a cost-utility analysis, an economic evaluation that estimates the cost per quality-adjusted life-year (QALY), and was designed to comply with Thai Health Technology Assessment Process Guidelines [6] . The Markov model was used to analyze the cost utility of the two treatment policies: providing and not providing factors concentrate for treating early bleeding episodes at home from the perspective of the Thai government.
The Markov model is a decision-analytical model used to estimate the cost-effectiveness of health care interventions. It is particularly suited to modeling chronic disease [7] . In a Markov model, a patient's possible prognosis is divided into distinct health states. Costs and benefits are assigned to each health state and move over a cycle until the last cycle is reached. The costs and benefits of comparative interventions are then estimated according to the time spent in each state.
The health states included in the Markov model are shown in Fig. 1 . The ovals represent the possible health states, and the arrows indicate the possible transition between those states. Lifethreatening bleeding is defined as hemorrhage or bleeding leading to death, requiring prompt hospital intervention, whereas emergency surgery is a surgical procedure that risks bleeding; thus, prevention of bleeding in the operation room is requested.
With a 1-year cycle length, the model was structured with the following assumptions:
1. All individuals entered the model in the health state "well." 2. At the following cycle, individuals remained in the health state well or entered the health states "life threatening" or "emergency surgery" or "death." 3. In each cycle, individuals in the life-threatening state may also receive emergency surgery and individuals in the emergency surgery state may also be in the life-threatening state. After the treatment, individuals can pass to the well state or death at the end of the cycle.
The cycle will run until the individual reaches the age of 99 years or is dead. Our model was run for a hypothetical cohort of 5000 Thai patients with hemophilia A and B who had no inhibitor or less than 5 BU, with the severity proportion of severe: moderate:mild patients at 40:38:22 [8] . Patients' severity was considered by level of clotting factor activity. Patients with less than 1% were classified as having severe hemophilia, those with 1% to 5% and more than 5% to 40% had moderate and mild hemophilia, respectively. The model was run to simulate two scenarios. Scenario 1 was for "no home-based care" in which patients were treated with blood components only when admitted at the hospital but no home treatment. Scenario 2 was for "home-based care" in which factors were prescribed and infused by patients for treatment of early bleeding episodes at home.
Transition Probabilities
The 1-year transition probability matrix is shown in Table 1 . Probability of death ( Table 2) was estimated from a life table for Thai population by age group [9] adjusted by available evidence of mortality rate in people with hemophilia A or B but without HIV infection in the United Kingdom [10] . Data of annual probability of requiring emergency surgery and life-threatening operation ( Table 3) were obtained from registered patients under the National Health Security Office (NHSO). The data were collected from electronic databases from 29 hospitals in 21 provinces in 2007 (n ¼ 328) [11] and from drug reimbursement data between 2007 and 2012 submitted to the NHSO (n ¼ 563) [8] .
Resource Use
Lifetime cost of treatment in this study was considered as factor concentrate provided for early treatment of bleeding episodes at home for the home-based care policy and treatment cost at hospitals for emergency surgery and life-threatening operation. Treatment cost at hospital comprised the cost of factor concentrate and other medications used, such as blood components, medicines, and medical supplies, and cost for laboratory tests, room, doctor fee, and so forth. The calculation is as follows:
Direct 
Cost of factor concentrate
Cost of factor concentrate used in the model was obtained from the Food and Drug Administration price quotation, which was 3424 and 6848 Thailand baht (THB) per vial, for 250 and 500 IU, respectively. Other direct medical costs and length of stay All other medical costs and patients' length of stay (LOS) were obtained from data of registered patients under the NHSO (Tables 4-6 ). Resource use was considered by patient's age. A child was defined as an individual younger than 10 years, whereas an adult was defined as an individual 10 years or older.
Utility
Because of the lack of utility data on health-related quality of life of Thai individuals with hemophilia A and B, the study, with the Ethics Committee approval from Ramathibodi Hospital, surveyed the quality of life of 105 Thai patients by mailed questionnaires. The response rate was 54.28% or 57 cases. The questionnaire had three parts: first was patient's demographic characteristics.
Second and third parts were the visual analogue scale before and after attending home-based care, respectively. The visual analogue scale was scored between 0 and 1, where 0 meant dead and 1 meant perfect life. Utility was then calculated as QALY ¼ quality of life Â life-year saved ( Table 7) .
Cost-Utility Analysis
Cost utility of the two policies for each severity level was calculated as cost per QALY by using the following equation: Lifetime cost of treatment/Utility (QALY).
In addition, to compare cost and utility between the policies, incremental cost-effectiveness ratio (ICER) was calculated as follows: (Lifetime cost of home-based care treatment À Lifetime cost of no home-based care treatment)/(Utility of home-based care À Utility of no home-based care)
All costs used in the study are in THB. Cost and utility values were adjusted to base year at 2012 with a 3% discount rate.
Sensitivity Analysis
One-way sensitivity analysis was performed for children with mild hemophilia, varying the discount rate (0%-6%), rate of hospitalization (95% confidence interval), LOS (95% confidence interval), and cost of factor concentrate (Ϯ10%). In addition, probabilistic sensitivity analysis was simulated by using the Monte-Carlo method. Using Microsoft Excel, the number was sampled 5000 times according to each parameter's distribution.
Results
The analysis showed that, on governmental perspective, expected lifetime costs of treating Thai patients with hemophilia A or B who had no inhibitor or less than 5 BU were 5.22 (for mild), 11.20 (for moderate), and 20.19 (for severe) million THB in case of providing factor concentrate for treating early bleeding episodes at home and were 5.00 (for mild), 13.66 (for moderate), and 25.91 (for severe) million THB in case of not providing factor concentrate at home ( Table 8 ). The associated QALYs were approximately 23.29 (for mild), 16.47 (for moderate), and 12.21 (for severe) in cases of no home-based care and 26.11 (for mild), 22.44 (for moderate), and 20.61 (for severe) in cases of home-based care.
The cost and utility given above produced a cost per QALY of 214,595 (for mild), 829,504 (for moderate), and 2,122,085 (for severe) THB in the no home-based care scenario and 200,103 (for mild), 499,157 (for moderate), and 979,557 (for severe) THB in the home-based care scenario. When comparing the two policies, an ICER was cost saving in moderate and severe cases and 80,542 THB per QALY gain in mild cases.
From one-way sensitivity analysis, in mild hemophilia, results were most sensitive to the rate of hospitalization (Fig. 2) followed by LOS, cost of factor concentrate, and discount rate, respectively.
With probabilistic sensitivity analysis, the home-based care policy was found to be more cost-effective than the no homebased care policy in any value of ceiling ratio (Fig 3) . 
Discussion
This study was conducted to assess the cost utility of providing versus not providing factor concentrate to treat patients with hemophilia A or B who had no inhibitor or less than 5 BU at home. The Markov model used data from different sources.
The analysis showed that cost per QALY of patients without home-based care was 214,595 to 2,122,085 THB and that of patients with home-based care was 200,103 to 979,557 THB. When comparing the two policies, an ICER was cost saving in moderate and severe cases and 80,542 THB per QALY gain in mild cases. In all patient groups, less than one time of gross domestic product per capita (120,000 THB per QALY gained) was found.
Compared with other Thai studies, in 2009, Suksriwong et al. [12] came up with the economics clinical and humanistic outcomes model, which was not a full economic evaluation to assess cost and utility of patients with hemophilia registered under the NHSO. After providing patients factor concentrate for treatment of early bleedings episodes at home, the number of patients needing hospitalization decreased from 5.19 to 2.65 times per year. In terms of utility, 77.9% of the patients said their life and family were better.
A number of economic evaluations of prophylaxis with factor concentrate were reported in other countries, mostly in patients with severe hemophilia. In 2002, Miners et al. [13] assessed the cost-effectiveness of primary prophylaxis with clotting factor instead of treatment following a bleeding episode for UK individuals with severe hemophilia using the Markov model in the societal perspective. The results showed that an additional £46,500 and £8,600 per QALY gained was needed for severe hemophilia A and B, respectively. In 2009, Miners [14] revisited the assessment to estimate the value of conducting research to reduce the parameter uncertainties and found that the ICER for patients with hemophilia A was approximately £37,000 (£10,000 lower than the value published in 2002).
Another full economics evaluation, in Italy, evaluated the cost-effectiveness of primary prophylaxis with factor VIII concentrates versus treatment following a bleeding episode in patients with severe hemophilia A in 2011. With the lifetime Markov model, the result showed that incremental cost per QALY gained was €40,229 [15] .
The results of our and other analysis revealed that prophylaxis in patients with severe hemophilia A is a cost-effective strategy compared with treatment following a bleeding episode, as demonstrated by the QALY values obtained.
Our model has a number of limitations mainly due to the assumptions made and the data used, some of which were derived from different sources. The possible direct nonmedical and indirect costs, such as traveling cost and caregiver and patient's productivity loss, were not considered in this study. Another important limitation is the assumptions on which the analysis was based to simplify the model or in case of incomplete data. Specifically, this regarded the death rate, derived from Thai population by age group and an available evidence of mortality rate in people with hemophilia A or B but without HIV in the United Kingdom.
Conclusions
In Thailand, it is cost saving to provide factor concentrate to patients with moderate and severe hemophilia A or B to treat their early bleeding episodes at home. In addition, it is also costeffective for mild hemophilia cases, with the ceiling threshold of one time of gross domestic product per capita (120,000 THB per QALY gained). The government should continue supporting "home-based care" programs originated by the NHSO and expand the coverage to all patients with hemophilia.
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